GSK329

GSK329 is a potent and selective diarylurea inhibitor of the cardiac-specific kinase TNNI3K. GSK329 exhibits positive cardioprotective outcomes in the model of ischemia/reperfusion cardiac injury[1].

Product Specifications

CAS Number

[1268490-12-5]

Product Name Alternative

CXD101

UNSPSC

12352005

Target

MAP3K

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/gsk329.html

Purity

99.60

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC(Cl)=C(C(Cl)=C1)OC2=NC=NC(NC)=C2)NC3=CC=CC(C(F)(F)F)=C3

Molecular Formula

C19H14Cl2F3N5O2

Molecular Weight

472.25

References & Citations

[1]Patterson JR, et, al. Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity Against VEGFR2, p38α, and B-Raf. J Med Chem. 2021 Nov 11;64 (21) :15651-15670.